Mednow Stock Price, News & Analysis

Mednow Inc. (OTCQX: MDNWF) has launched its largest technology update, focusing on caregivers in Canada. This new feature suite allows users to manage multiple medication profiles from a single account, simplifying the administrative tasks for those looking after dependents. The upgrade includes tools for tracking medication, refilling prescriptions, and consultations with pharmacists. Additionally, it enhances partnerships with Medvisit for homebound patients. Mednow also plans to introduce a fee-based elder care product later this year. This latest release aims to improve healthcare delivery and streamline services for caregivers, especially for Canada’s aging population.

Mednow Inc. (OTCQX: MDNWF) has launched an enhanced Virtual Diabetes Management program that integrates Dexcom G6 real-time continuous glucose monitoring (rtCGM) supplies and diabetes support services. This program offers convenient home delivery and access to certified diabetes educators and clinical pharmacists for personalized care. Initially available in Ontario and British Columbia from early February, the integration aims to improve accessibility and management for diabetes patients. The partnership with Dexcom aims to leverage their technology to enhance patient care and support effective diabetes management.

Mednow Inc (TSXV: MNOW, OTCQX: MDNWF) supports Ontario's new pharmacist practice expansion starting January 1, allowing pharmacists to assess and prescribe for 13 minor ailments, including UTIs and cold sores. Patients with valid Ontario health cards benefit from publicly funded services without out-of-pocket costs. This initiative improves access to healthcare and enables Mednow to expand its virtual care program, leveraging its existing Nurse Practitioner services. The company anticipates cost savings and a new revenue stream through Ontario Drug Benefits reimbursement for these services.

Mednow Inc. (TSXV:MNOW, OTCQX:MDNWF) expands services through its Medvisit platform, Canada's largest home visit doctor service. The new at-home medication review program, under the Ontario Drug Benefits Program, enables pharmacists to manage medication for housebound patients, enhancing care efficiency. Medvisit, operational for over 30 years, has served over 400,000 patients. Additionally, Mednow has amended its private placement offering of secured convertible debentures to up to $4,000,000 to support strategic acquisitions and working capital.

Mednow Inc. (TSXV: MNOW, OTCQX: MDNWF) will host its quarterly conference call on January 18, 2023, at 8:30 AM EST. The call will discuss the first-quarter financial results and updates on Mednow's expansion, strategic partnerships, and M&A activities. Investors can join via a toll-free number or international line. For financial results, visit Mednow's website. Mednow is a healthcare technology company offering virtual pharmacy services to enhance patient care.

Mednow Inc. (OTCQX:MDNWF) partners with Care Pharmacies to enhance its virtual pharmacy network across Canada. This collaboration aims to improve pharmacy distribution and access through a Preferred Pharmacy Network (PPN), expanding Mednow's services to more Canadians. Mednow will charge technology fees to participating pharmacies, further boosting its revenue streams. However, the company is currently under a Management Cease Trade Order (MCTO) due to delays in filing interim financial statements, impacting its operational transparency.

Mednow Inc. (OTCQX: MDNWF) announced a likely delay in filing its unaudited interim financial statements due by December 30, 2022, due to complications with its auditors. The company has applied for a Management Cease Trade Order (MCTO) under National Policy 12-203 and expects to file by January 31, 2023. During the MCTO, while general trading of its shares will continue, trading restrictions will apply to senior management. The company has also changed its auditor from MNP LLP to SRCO Professional Corporation effective December 5, 2022.

Mednow (TSXV:MNOW, OTCQX:MDNWF) reported a significant financial performance in Q4 2022, with revenue increasing by 11% quarter-over-quarter to $7,206,664, and a remarkable 5,700% year-over-year growth. Patient count surged by over 35% to approximately 31,000. Despite these highlights, the company posted an EBITDA loss of $13,319,073 for the year. Strategic moves include partnerships with Aya and investments in technology to establish a digital pharmacy infrastructure.

Mednow Inc. (TSXV: MNOW, OTCQX: MDNWF) will host its quarterly conference call on November 29, 2022, at 8:30 AM EST to discuss fourth-quarter 2022 financial results. The call will include updates on the company's expansion, strategic partnerships, milestones, and M&A activities. Interested parties can dial in using the provided numbers to catch the insights shared by Mednow's team. Financial results will be available on the company's website post-call.